BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 19090009)

  • 1. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.
    Perez DG; Suman VJ; Fitch TR; Amatruda T; Morton RF; Jilani SZ; Constantinou CL; Egner JR; Kottschade LA; Markovic SN
    Cancer; 2009 Jan; 115(1):119-27. PubMed ID: 19090009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775.
    Kottschade LA; Suman VJ; Perez DG; McWilliams RR; Kaur JS; Amatruda TT; Geoffroy FJ; Gross HM; Cohen PA; Jaslowski AJ; Kosel ML; Markovic SN
    Cancer; 2013 Feb; 119(3):586-92. PubMed ID: 22915053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1).
    Kottschade LA; Suman VJ; Amatruda T; McWilliams RR; Mattar BI; Nikcevich DA; Behrens R; Fitch TR; Jaslowski AJ; Markovic SN
    Cancer; 2011 Apr; 117(8):1704-10. PubMed ID: 21472717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study.
    Croghan GA; Suman VJ; Maples WJ; Albertini M; Linette G; Flaherty L; Eckardt J; Ma C; Markovic SN; Erlichman C
    Cancer; 2010 Jul; 116(14):3463-8. PubMed ID: 20564112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.
    Kim KB; Sosman JA; Fruehauf JP; Linette GP; Markovic SN; McDermott DF; Weber JS; Nguyen H; Cheverton P; Chen D; Peterson AC; Carson WE; O'Day SJ
    J Clin Oncol; 2012 Jan; 30(1):34-41. PubMed ID: 22124101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
    Sandler A; Gray R; Perry MC; Brahmer J; Schiller JH; Dowlati A; Lilenbaum R; Johnson DH
    N Engl J Med; 2006 Dec; 355(24):2542-50. PubMed ID: 17167137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
    Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
    J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary results of the combination of bevacizumab and weekly Paclitaxel in advanced melanoma.
    González-Cao M; Viteri S; Díaz-Lagares A; González A; Redondo P; Nieto Y; Espinós J; Chopitea A; Ponz M; Martín-Algarra S
    Oncology; 2008; 74(1-2):12-6. PubMed ID: 18536525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma.
    Spitler LE; Boasberg P; O'Day S; Hamid O; Cruickshank S; Mesko S; Weber RW
    Am J Clin Oncol; 2015 Feb; 38(1):61-7. PubMed ID: 25616203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group.
    Saloustros E; Nikolaou M; Kalbakis K; Polyzos A; Christofillakis C; Kentepozidis N; Pistamaltzian N; Kourousis C; Vamvakas L; Georgoulias V; Mavroudis D
    Clin Breast Cancer; 2018 Feb; 18(1):88-94. PubMed ID: 29153775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporation of bevacizumab in the primary treatment of ovarian cancer.
    Burger RA; Brady MF; Bookman MA; Fleming GF; Monk BJ; Huang H; Mannel RS; Homesley HD; Fowler J; Greer BE; Boente M; Birrer MJ; Liang SX;
    N Engl J Med; 2011 Dec; 365(26):2473-83. PubMed ID: 22204724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.
    Penson RT; Dizon DS; Cannistra SA; Roche MR; Krasner CN; Berlin ST; Horowitz NS; Disilvestro PA; Matulonis UA; Lee H; King MA; Campos SM
    J Clin Oncol; 2010 Jan; 28(1):154-9. PubMed ID: 19917843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.
    Gonzalez-Martin A; Gladieff L; Tholander B; Stroyakovsky D; Gore M; Scambia G; Kovalenko N; Oaknin A; Ronco JP; Freudensprung U; Pignata S;
    Eur J Cancer; 2013 Dec; 49(18):3831-8. PubMed ID: 24007819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site.
    Hainsworth JD; Spigel DR; Thompson DS; Murphy PB; Lane CM; Waterhouse DM; Naot Y; Greco FA
    Oncologist; 2009 Dec; 14(12):1189-97. PubMed ID: 19965914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
    Cohen MH; Gootenberg J; Keegan P; Pazdur R
    Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 3 trial of bevacizumab in ovarian cancer.
    Perren TJ; Swart AM; Pfisterer J; Ledermann JA; Pujade-Lauraine E; Kristensen G; Carey MS; Beale P; Cervantes A; Kurzeder C; du Bois A; Sehouli J; Kimmig R; Stähle A; Collinson F; Essapen S; Gourley C; Lortholary A; Selle F; Mirza MR; Leminen A; Plante M; Stark D; Qian W; Parmar MK; Oza AM;
    N Engl J Med; 2011 Dec; 365(26):2484-96. PubMed ID: 22204725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
    Herbst RS; Redman MW; Kim ES; Semrad TJ; Bazhenova L; Masters G; Oettel K; Guaglianone P; Reynolds C; Karnad A; Arnold SM; Varella-Garcia M; Moon J; Mack PC; Blanke CD; Hirsch FR; Kelly K; Gandara DR
    Lancet Oncol; 2018 Jan; 19(1):101-114. PubMed ID: 29169877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanoma.
    McWilliams RR; Allred JB; Slostad JA; Katipamula R; Dronca RS; Rumilla KM; Erickson LA; Bryce AH; Joseph RW; Kottschade LA; King DM; Leitch JM; Markovic SN
    Cancer; 2018 Feb; 124(3):537-545. PubMed ID: 29044496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma: a phase II trial of the Sarah Cannon Research Institute Oncology Research Consortium.
    Hauke RJ; Infante JR; Rubin MS; Shih KC; Arrowsmith ER; Hainsworth JD
    Melanoma Res; 2013 Dec; 23(6):468-73. PubMed ID: 23969699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies.
    Bhatty M; Kato S; Piha-Paul SA; Naing A; Subbiah V; Huang HJ; Karp DD; Tsimberidou AM; Zinner RG; Hwu WJ; Javle M; Patel SP; Hu MI; Varadhachary GR; Conley AP; Ramzanali NM; Holley VR; Kurzrock R; Meric-Bernstam F; Kwang Chae Y; Kim KB; Falchook GS; Janku F
    Cancer; 2019 Feb; 125(3):463-472. PubMed ID: 30383888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.